-
Inter beat Kairat Almaty to maintain Champions League perfection
-
Newcastle sink Bilbao to extend Champions League winning run
-
Wall Street stocks rebound after positive jobs data
-
LPGA, European tour partner with Saudis for new Vegas event
-
Eyes turn to space to feed power-hungry data centers
-
Jazz lose Kessler for season with shoulder injury
-
League scoring leader Messi among MLS Best XI squad
-
MLS bans Suarez for Miami's winner-take-all playoff match
-
McIlroy appreciates PGA of America apology for Ryder Cup abuse
-
Garnacho equaliser saves Chelsea in Qarabag draw
-
Promotions lift McDonald's sales in tricky consumer market
-
Five things to know about New York's new mayor
-
Anisimova beats Swiatek to reach WTA Finals last four
-
US Supreme Court appears skeptical of Trump tariff legality
-
AC Milan post third straight annual profit on day of San Siro purchase
-
Angelina Jolie visits Ukrainian frontline city, media reports say
-
UN says forests should form key plank of COP30
-
Star designer Rousteing quits fashion group Balmain
-
Mexico's Sheinbaum steps up cartel fight after murder of anti-narco mayor
-
Attack on funeral in Sudan's Kordofan region kills 40: UN
-
Key PSG trio set for spell on sidelines
-
Democrats punch back in US elections - and see hope for 2026
-
BMW reports rising profitability, shares jump
-
Bolivia Supreme Court orders release of jailed ex-president Jeanine Anez
-
Wall Street stocks rise after positive jobs data
-
'Hostage diplomacy': longstanding Iran tactic presenting dilemma for West
-
Rybakina stays perfect at WTA Finals with win over alternate Alexandrova
-
Le Garrec welcomes Dupont help in training for Springboks showdown
-
Brussels wants high-speed rail linking EU capitals by 2040
-
Swiss business chiefs met Trump on tariffs: Bern
-
Spain's exiled king recounts history, scandals in wistful memoir
-
Wall Street stocks steady after positive jobs data
-
Trump blasts Democrats as government shutdown becomes longest ever
-
Indian pilgrims find 'warm welcome' in Pakistan despite tensions
-
Inter and AC Milan complete purchase of San Siro
-
Swedish authorities inspect worksite conditions at steel startup Stegra
-
Keys withdraws from WTA Finals with illness
-
Prince Harry says proud to be British despite new life in US
-
EU strikes last-ditch deal on climate targets as COP30 looms
-
Stocks retreat as tech bubble fears grow
-
Shein opens first permanent store amid heavy police presence
-
West Indies edge New Zealand despite Santner brilliance
-
French pair released by Iran await return home
-
German factory orders up but outlook still muted
-
Death toll tops 100 as Philippines digs out after typhoon
-
Attack on key city in Sudan's Kordofan region kills 40: UN
-
'No one could stop it': Sudanese describe mass rapes while fleeing El-Fasher
-
Champagne and cheers across New York as Mamdani soars to victory
-
Medieval tower collapse adds to Italy's workplace toll
-
BMW boosts profitability despite China, tariff woes
More Ebola trial vaccines arrive in Uganda
Uganda announced Thursday that it had received shipments of two more trial vaccines to test against a strain of Ebola responsible for dozens of deaths in the East African nation.
Since authorities declared an Ebola outbreak on September 20, Uganda has registered 142 confirmed cases and 56 deaths, but the spread has slowed in recent weeks, sparking hope that the epidemic could be on its way out.
The outbreak has been caused by the so-called Sudan strain of the virus, for which there is currently no vaccine.
But three candidate vaccines -- one developed by Oxford University and the Jenner Institute in Britain, another from the Sabin Vaccine Institute in the United States, and a third from the International AIDS Vaccine Initiative (IAVI) -- will be trialed in Uganda in the coming weeks.
On December 8, Uganda received its first shipment of doses from the Sabin Vaccine Institute.
"On Saturday December 17, we received two more candidate vaccines from Merck/IAVI of 2,160 doses and 2,000 doses from Oxford University/Jenner Institute manufactured by the Serum Institute of India," Health Minister Jane Ruth Aceng told a press briefing on Thursday.
They will be used in a so-called ring vaccination trial, where all contacts of confirmed Ebola patients, and contacts of contacts, are jabbed along with frontline and health workers.
Ugandan authorities said last month that new cases were falling, and the last confirmed patient with the disease was discharged from hospital on November 30.
The absence of active Ebola cases in recent days has held up the vaccine trials, according to international health experts working in Uganda.
Aceng said however that the authorities had already begun enlisting volunteers for the trials, adding that Uganda would take part in a global expert consultation meeting on Ebola on January 12.
The government last week lifted a two-month lockdown on two Ebola hotspots, removing curbs including a dusk-to-dawn curfew, a ban on personal travel and the closure of markets, bars and churches.
According to the World Health Organization (WHO), an outbreak of the disease ends when there are no new cases for 42 consecutive days -- twice the incubation period of Ebola.
Ebola spreads through bodily fluids. Common symptoms are fever, vomiting, bleeding and diarrhoea.
Outbreaks are difficult to contain, especially in urban environments.
Y.Bouchard--BTB